Diagnostic Value of Serum Level of Soluble Tumor Necrosis Factor Receptor IIα in Egyptian Patients With Chronic Hepatitis C Virus Infection and Hepatocellular Carcinoma

Authors Information
Article Notes and Dates
To Cite : Fouad S A, Elsaaid N H, Mohamed N A, Abutaleb O M. Diagnostic Value of Serum Level of Soluble Tumor Necrosis Factor Receptor IIα in Egyptian Patients With Chronic Hepatitis C Virus Infection and Hepatocellular Carcinoma, Hepat Mon. 2014 ;14(9):e19346. doi: 10.5812/hepatmon.19346.
Copyright: Copyright © 2014, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
Abstract
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Di Bisceglie AM. Hepatitis C. Lancet. 1998; 351(9099): 351-5
  • 2. Flamm SL. Chronic hepatitis C virus infection. JAMA. 2003; 289(18): 2413-7[DOI][PubMed]
  • 3. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005; 5(9): 558-67[DOI][PubMed]
  • 4. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000; 355(9207): 887-91[PubMed]
  • 5. Nafeh MA, Medhat A, Shehata M, Mikhail NN, Swifee Y, Abdel-Hamid M, et al. Hepatitis C in a community in Upper Egypt: I. Cross-sectional survey. Am J Trop Med Hyg. 2000; 63(5-6): 236-41[PubMed]
  • 6. Abdel-Aziz F, Habib M, Mohamed MK, Abdel-Hamid M, Gamil F, Madkour S, et al. Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatology. 2000; 32(1): 111-5[DOI][PubMed]
  • 7. el-Sadawy M, Ragab H, el-Toukhy H, el-Mor Ael L, Mangoud AM, Eissa MH, et al. Hepatitis C virus infection at Sharkia Governorate, Egypt: seroprevalence and associated risk factors. J Egypt Soc Parasitol. 2004; 34(1 Suppl): 367-84[PubMed]
  • 8. Deuffic-Burban S, Mohamed MK, Larouze B, Carrat F, Valleron AJ. Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections. J Hepatol. 2006; 44(3): 455-61[DOI][PubMed]
  • 9. Bruix J. Treatment of hepatocellular carcinoma. Hepatology. 1997; 25(2): 259-62[DOI][PubMed]
  • 10. Villeneuve JP, Desrochers M, Infante-Rivard C, Willems B, Raymond G, Bourcier M, et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology. 1994; 106(4): 1000-5[PubMed]
  • 11. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology. 1995; 22(2): 432-8[PubMed]
  • 12. Kato Y, Nakata K, Omagari K, Furukawa R, Kusumoto Y, Mori I, et al. Risk of hepatocellular carcinoma in patients with cirrhosis in Japan. Analysis of infectious hepatitis viruses. Cancer. 1994; 74(8): 2234-8[PubMed]
  • 13. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985; 56(4): 918-28[PubMed]
  • 14. Calvet X, Bruix J, Gines P, Bru C, Sole M, Vilana R, et al. Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients. Hepatology. 1990; 12(4 Pt 1): 753-60[PubMed]
  • 15. Gebo KA, Chander G, Jenckes MW, Ghanem KG, Herlong HF, Torbenson MS, et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology. 2002; 36(5 Suppl 1)-92[DOI][PubMed]
  • 16. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology. 1998; 27(1): 273-8[DOI][PubMed]
  • 17. Aref S, Menessy A. Correlation of soluble IL-2R and tumor necrosis factor α receptor (TNF-αR) levels with severity of chronic hepatitis C liver injury. Egypt J Hematol. 1997; 22: 327-40
  • 18. Quentmeier H, Dirks WG, Fleckenstein D, Zaborski M, Drexler HG. Tumor necrosis factor-alpha-induced proliferation requires synthesis of granulocyte-macrophage colony-stimulating factor. Exp Hematol. 2000; 28(9): 1008-15[PubMed]
  • 19. Beutler B, van Huffel C. Unraveling function in the TNF ligand and receptor families. Science. 1994; 264(5159): 667-8[PubMed]
  • 20. Berg T, Muller AR, Platz KP, Hohne M, Bechstein WO, Hopf U, et al. Dynamics of GB virus C viremia early after orthotopic liver transplantation indicates extrahepatic tissues as the predominant site of GB virus C replication. Hepatology. 1999; 29(1): 245-9[DOI][PubMed]
  • 21. Cole LA. New discoveries on the biology and detection of human chorionic gonadotropin. Reprod Biol Endocrinol. 2009; 7: 8[DOI][PubMed]
  • 22. Heemann C, Kreuz M, Stoller I, Schoof N, von Bonin F, Ziepert M, et al. Circulating levels of TNF receptor II are prognostic for patients with peripheral T-cell non-Hodgkin lymphoma. Clin Cancer Res. 2012; 18(13): 3637-47[DOI][PubMed]
  • 23. Knapp RG, Miller C, Clinton M. Clinical epidemiology and biostatistics. 1992;
  • 24. Tilg H, Wilmer A, Vogel W, Herold M, Nolchen B, Judmaier G, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology. 1992; 103(1): 264-74[PubMed]
  • 25. Jacobson Brown PM, Neuman MG. Immunopathogenesis of hepatitis C viral infection: Th1/Th2 responses and the role of cytokines. Clin Biochem. 2001; 34(3): 167-71[PubMed]
  • 26. Budhu A, Wang XW. The role of cytokines in hepatocellular carcinoma. J Leukoc Biol. 2006; 80(6): 1197-213[DOI][PubMed]
  • 27. Zekri AR, El-Din HM, Bahnassy AA, El-Shehabi AM, El-Leethy H, Omar A, et al. TRUGENE sequencing versus INNO-LiPA for sub-genotyping of HCV genotype-4. J Med Virol. 2005; 75(3): 412-20[DOI][PubMed]
  • 28. Beutler B. TNF, immunity and inflammatory disease: lessons of the past decade. J Investig Med. 1995; 43(3): 227-35[PubMed]
  • 29. Sarvari J, Mojtahedi Z, Taghavi SA, Kuramitsu Y, Shamsi Shahrabadi M, Ghaderi A, et al. Differentially Expressed Proteins in Chronic Active Hepatitis, Cirrhosis, and HCC Related to HCV Infection in Comparison With HBV Infection: A proteomics study. Hepat Mon. 2013; 13(7)[DOI][PubMed]
  • 30. Morshed SA, Fukuma H, Kimura Y, Watanabe S, Nishioka M. Interferon-gamma, interleukin (IL)-2 and IL-2 receptor expressions in hepatitis C virus-infected liver. Gastroenterol Jpn. 1993; 28 Suppl 5: 59-66[PubMed]
  • 31. Zekri AR, Alam El-Din HM, Bahnassy AA, Zayed NA, Mohamed WS, El-Masry SH, et al. Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4. Comp Hepatol. 2010; 9(1): 1[DOI][PubMed]
  • 32. Ren Y, Poon RT, Tsui HT, Chen WH, Li Z, Lau C, et al. Interleukin-8 serum levels in patients with hepatocellular carcinoma: correlations with clinicopathological features and prognosis. Clin Cancer Res. 2003; 9(16 Pt 1): 5996-6001[PubMed]
  • 33. Akiba J, Yano H, Ogasawara S, Higaki K, Kojiro M. Expression and function of interleukin-8 in human hepatocellular carcinoma. Int J Oncol. 2001; 18(2): 257-64[PubMed]
  • 34. Kallinowski B, Haseroth K, Marinos G, Hanck C, Stremmel W, Theilmann L, et al. Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection. Clin Exp Immunol. 1998; 111(2): 269-77[PubMed]
  • 35. Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011; 140(4): 1182-1188 e1[DOI][PubMed]
  • 36. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010; 138(2): 513-21[DOI][PubMed]
  • 37. Sakisaka S, Watanabe M, Tateishi H, Harada M, Shakado S, Mimura Y, et al. Erythropoietin production in hepatocellular carcinoma cells associated with polycythemia: immunohistochemical evidence. Hepatology. 1993; 18(6): 1357-62[PubMed]
  • 38. Pratt D, Kaplan M. Schiff's Diseases of the Liver. 2011; : 205
  • 39. Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology. 2005; 41(3): 553-8[DOI][PubMed]
  • 40. Sugiyama M, Kanno T, Ohkubo A, Muto Y, Murata K, Ueno Y. [The clinical usefulness of the molar ratio of branched-chain amino acids to tyrosine (BTR) in discriminating stage of chronic liver diseases]. Rinsho Byori. 1992; 40(6): 673-8[PubMed]
  • 41. Young KC, Lin PW, Hsiao WC, Chang TT, Chang YC, Wu HL. Variation of hepatitis C virus load, hypervariable region 1 quasispecies and CD81 hepatocyte expression in hepatocellular carcinoma and adjacent non-cancerous liver. J Med Virol. 2002; 68(2): 188-96[DOI][PubMed]
  • 42. Tangkijvanich P, Anukulkarnkusol N, Suwangool P, Lertmaharit S, Hanvivatvong O, Kullavanijaya P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol. 2000; 31(4): 302-8[PubMed]
  • 43. Itoh Y, Okanoue T, Ohnishi N, Sakamoto M, Nishioji K, Nakagawa Y, et al. Serum levels of soluble tumor necrosis factor receptors and effects of interferon therapy in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 1999; 94(5): 1332-40[DOI][PubMed]
  • 44. Aderka D, Wysenbeek A, Engelmann H, Cope AP, Brennan F, Molad Y, et al. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum. 1993; 36(8): 1111-20[PubMed]
  • 45. Suruki RY, Mueller N, Hayashi K, Harn D, DeGruttola V, Raker CA, et al. Host immune status and incidence of hepatocellular carcinoma among subjects infected with hepatitis C virus: a nested case-control study in Japan. Cancer Epidemiol Biomarkers Prev. 2006; 15(12): 2521-5[DOI][PubMed]
  • 46. Kakumu S, Okumura A, Ishikawa T, Yano M, Enomoto A, Nishimura H, et al. Serum levels of IL-10, IL-15 and soluble tumour necrosis factor-alpha (TNF-alpha) receptors in type C chronic liver disease. Clin Exp Immunol. 1997; 109(3): 458-63[PubMed]
  • 47. Macias J, Sanchez-Quijano A, Pineda JA, Abad MA, Rubio A, Rosa R, et al. Minimal liver injury in chronic hepatitis C virus infection is associated with low levels of soluble TNF-alpha/Fas receptors and acquisition in childhood. Liver. 2001; 21(6): 410-4[PubMed]
  • 48. Luo JL, Maeda S, Hsu LC, Yagita H, Karin M. Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell. 2004; 6(3): 297-305[DOI][PubMed]
  • 49. Herbein G, O'Brien WA. Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis. Proc Soc Exp Biol Med. 2000; 223(3): 241-57[PubMed]
  • 50. Tateishi R, Yoshida H, Matsuyama Y, Mine N, Kondo Y, Omata M. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatol Int. 2008; 2(1): 17-30[DOI][PubMed]
  • 51. Snowberger N, Chinnakotla S, Lepe RM, Peattie J, Goldstein R, Klintmalm GB, et al. Alpha fetoprotein, ultrasound, computerized tomography and magnetic resonance imaging for detection of hepatocellular carcinoma in patients with advanced cirrhosis. Aliment Pharmacol Ther. 2007; 26(9): 1187-94[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

Hepatitis Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check